INCYTE CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.04 USD | +1.84% |
|
+4.19% | -3.08% |
| 02:55pm | Incyte Reports Tender Offer Results | MT |
| Jun. 11 | Incyte Reports Preliminary Tender Offer Results | MT |
Financials (USD)
| Sales 2024 * | 4.09B | Sales 2025 * | 4.52B | Capitalization | 13.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 807M | Net income 2025 * | 955M | EV / Sales 2024 * | 2.36 x |
| Net cash position 2024 * | 3.83B | Net cash position 2025 * | 5.41B | EV / Sales 2025 * | 1.79 x |
| P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
14.8
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +1.18% | ||
| 1 week | +3.57% | ||
| Current month | +4.68% | ||
| 1 month | +5.03% | ||
| 3 months | +2.67% | ||
| 6 months | -5.76% | ||
| Current year | -3.66% |
1 week
57.97
60.66
1 month
56.3760.66
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 15-03-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 208 M€ | +12.15% | - | |
| 2.94% | 1 M€ | +0.84% | - | |
| 2.88% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 60.88 | +1.57% | 705 847 |
| 24-06-12 | 59.94 | +0.77% | 6,112,135 |
| 24-06-11 | 59.48 | +0.13% | 9,175,728 |
| 24-06-10 | 59.4 | +0.41% | 10,170,965 |
| 24-06-07 | 59.16 | +1.28% | 8,706,264 |
Delayed Quote Nasdaq, June 13, 2024 at 10:19 am EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
59.94
USD
Average target price
72.8
USD
Spread / Average Target
+21.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.66% | 13.48B | |
| +0.46% | 91.38B | |
| -2.37% | 38.68B | |
| -11.22% | 33.58B | |
| +72.56% | 27.84B | |
| -13.04% | 16.05B | |
| -10.83% | 11.73B | |
| +180.20% | 10.74B | |
| -48.60% | 10.39B | |
| +2.10% | 8.94B |
- Stock Market
- Equities
- INCY Stock
